Thalamic atrophy is associated with development of clinically definite multiple sclerosis

Radiology

Volumn 268, Issue 3, 2013, Pages 831-841

  Zivadinov, Robert ^a   Havrdová, Eva ^b   Bergsland, Niels ^a   Tyblova, Michaela ^b   Hagemeier, Jesper ^a   Seidl, Zdenek ^b   Dwyer, Michael G ^a   Vaneckova, Manuela ^b   Krasensky, Jan ^d   Carl, Ellen ^a   Kalincik, Tomas ^c   Horáková, Dana ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX ATROPHY; BRAIN DAMAGE; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; INFORMED CONSENT; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; MCDONALD DIAGNOSTIC CRITERIA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; SCORING SYSTEM; STEROID THERAPY; THALAMIC ATROPHY; THALAMUS;

ADOLESCENT; ADULT; ATROPHY; CAUSALITY; COMORBIDITY; CZECH REPUBLIC; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THALAMUS;

EID: 84883183367     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122424     Document Type: Article

References (39)

1. Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009;282(1-2): 12-20.
2. Zivadinov R, Pirko I. Advances in understanding gray matter pathology in multiple sclerosis: are we ready to redefine disease pathogenesis? BMC Neurol 2012;12:9.
3. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3): 255-265.
4. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64(3): 247-254.
5. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 2008;79(4): 407-414.
6. Hulst HE, Geurts JJ. Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol 2011;11:153.
7. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012;12:11.
8. Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282(1-2): 61-66.
9. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79(11): 1236-1244.
10. Ramasamy DP, Benedict RH, Cox JL, et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a casecontrol study. J Neurol Sci 2009;282(1- 2): 47-54.
11. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254(9): 1212-1220.
12. Fisniku LK, Altmann DR, Cercignani M, et al. Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler 2009;15(6): 668-677.
13. Bergsland N, Horakova D, Dwyer MG, et al. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2012;33(8): 1573-1578.
14. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77(3): 257-263.
15. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127(Pt 5): 1101-1107.
16. Minagar A, Barnett MH, Benedict RH, et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013;80(2): 210-219.
17. Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010;257(2): 463-469.
18. Mesaros S, Rocca MA, Pagani E, et al. Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. AJNR Am J Neuroradiol 2011;32(6): 1016-1020.
19. Mesaros S, Rocca MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70(13 Pt 2): 1107-1112.
20. Aubert-Broche B, Fonov V, Ghassemi R, et al. Regional brain atrophy in children with multiple sclerosis. Neuroimage 2011;58(2): 409-415.
21. Horakova D, Zivadinov R, Weinstock-Guttman B, et al. HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol 2011;236(1-2): 76-80.
22. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343(13): 898-904.
23. Kalincik T, Vaneckova M, Tyblova M, et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS ONE 2012;7(11):e50101.
24. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58(6): 840-846.
25. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2): 292-302.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57(1): 289-300.
27. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52(5): 650-653.
28. Gilmore CP, Donaldson I, Bö L, Owens T, Lowe J, Evangelou N. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 2009;80(2): 182-187.
29. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2): 136-144.
30. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73(2): 141-147.
31. Magnano C, Schirda C, Weinstock-Guttman B, et al. Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging 2012;36(4): 825-834.
32. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365(23): 2188-2197.
33. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9444): 1489-1496.
34. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57(7): 1239-1247.
35. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17(2): 825-841.
36. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17(1): 479-489.
37. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59(1): 331-339.
38. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation- maximization algorithm. IEEE Trans Med Imaging 2001;20(1): 45-57.
39. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56(3): 907-922.